Companies · Biotechnology

Liquidia Corp

Morrisville · Biotechnology

Diligence memoA one-page analyst read on Liquidia Corp — recommendation, valuation, rhythm, risks.
$21.7M
Total raised · real
1
Rounds
Latest step-up
Top 32%
Sector rank · raised
Series B
Latest stage · inferred · Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Liquidia Corp looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.00× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era.
  • Within the normal band (100% of peer median) for its niche.
Dormant
  • Last raise 5.2 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Liquidia Corp is one of 4291 Biotechnology companies tracked from Morrisville. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2020
Year incorporated
2021-04-13
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2021-04-13 Raised $22M (real) Modeled valuation $616M (est)$22M$616MSeries B2021

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$21.7M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$616.1M
Base estimate est.
$43.5M
Conservative case
$2.0B
Upside case
$120.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
5.2 yr
Elapsed time used
5.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
5.2 yr
On record since
2021
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.0× above median
This company$21.7M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.2× above median
This company$21.7M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 9.6× above median
This company$616.1M
Sector median$64.2M

Raised more than 69% of sector peers (real $). Modeled value above 85% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #58 of 118.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Pandion Therapeutics Holdco LLC · Series B Raised $40.0M · modeled $1.6B (est)Ocular Therapeutix, Inc · Series B Raised $81.0M · modeled $1.5B (est)Insilico Medicine Cayman TopCo · Series B Raised $36.8M · modeled $1.5B (est)Purigen Biosystems, Inc. · Series B Raised $61.9M · modeled $1.4B (est)Lucira Health, Inc. · Series B Raised $32.5M · modeled $1.3B (est)Peptilogics, Inc. · Series B Raised $40.9M · modeled $1.2B (est)Nanotech Energy, Inc. · Series B Raised $31.6M · modeled $1.1B (est)Windtree Therapeutics Inc /De/ · Series B Raised $104.5M · modeled $1.0B (est)Liminal BioSciences Inc. · Series B Raised $67.1M · modeled $1.0B (est)Palladio Biosciences, Inc. · Series B Raised $28.0M · modeled $1.0B (est)Faze Medicines, Inc. · Series B Raised $30.4M · modeled $998.4M (est)Inivata Ltd · Series B Raised $25.0M · modeled $992.2M (est)Liquidia Corp (this company) Raised $21.7M · modeled $616.1M (est)Liquidia Corp
CompanyStageRaised · realValue · estvs peer med.
Pandion Therapeutics Holdco LLCSeries B$40.0M$1.6B2.58×
Ocular Therapeutix, IncSeries B$81.0M$1.5B2.42×
Insilico Medicine Cayman TopCoSeries B$36.8M$1.5B2.37×
Purigen Biosystems, Inc.Series B$61.9M$1.4B2.22×
Lucira Health, Inc.Series B$32.5M$1.3B2.10×
Peptilogics, Inc.Series B$40.9M$1.2B1.90×
Nanotech Energy, Inc.Series B$31.6M$1.1B1.82×
Windtree Therapeutics Inc /De/Series B$104.5M$1.0B1.71×
Liminal BioSciences Inc.Series B$67.1M$1.0B1.67×
Palladio Biosciences, Inc.Series B$28.0M$1.0B1.63×
Faze Medicines, Inc.Series B$30.4M$998.4M1.62×
Inivata LtdSeries B$25.0M$992.2M1.61×
Liquidia Corp this companySeries B$21.7M$616.1M1.00×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$21.7M2021-04-13$120.8M$616.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$21.7M2021-04-13
    • First recorded raise — entered as Series B.
    • 4 investors on this round.
Intelligence
Modeled next raise
$34.8M
Modeled next size est.range $22.6M$55.6M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Stephen Bloch14 other2021-04
David B. Johnson5 other2021-04
Paul B. Manning5 other2021-04
Arthur A. Kirsch1 other2021-04
Michael Kaseta1 other2021-04
Roger A. Jeffs1 other2021-04
Damian deGoa2021-04
Joanna Horobin2021-04
Katherine Rielly-Gauvin2021-04
Raman B. Singh2021-04
Registry & provenance

Liquidia Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1819576
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Liquidia Technologies IncBiotechnologySeries B$86.7M$890.0Mnetwork2 shared operators · same sector · same stage
Xalud Therapeutics, Inc.BiotechnologySeries B$30.5M$494.5Mnetwork1 shared operator · same sector · same stage
Iantrek, Inc.BiotechnologySeries B$58.2M$152.2Mnetwork1 shared operator · same sector · same stage
EvolveImmune Therapeutics Holding Company, LLCBiotechnologySeries B$85.8M$124.8Mnetwork1 shared operator · same sector · same stage
Evergaze Holdings LLCBiotechnologySeries B$21.7M$793.8Msame sector · same stage
Envisagenics, Inc.BiotechnologySeries B$21.7M$449.5Msame sector · same stage
Amarillo Biosciences IncBiotechnologySeries B$21.8M$565.6Msame sector · same stage
Culture Biosciences Inc.BiotechnologySeries B$21.6M$857.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Liquidia Technologies IncBiotechnologySeries B$890.0M99%
Liquid BioScience, Inc.BiotechnologySeries B$1.6B91%
Liquid Genomics, Inc.BiotechnologySeed$72.3M89%
BioCardia, Inc.BiotechnologySeries B$158.8M87%
PierianDx, Inc.BiotechnologySeries B$442.8M85%
BALX Holdings, LLCBiotechnologySeries A$72.3M85%
LexaGene Holdings Inc.BiotechnologySeries A$18.7M85%
MetaBiotech CorpBiotechnologySeries A$331.8M84%
Frequently asked
How much funding has Liquidia Corp raised?
Liquidia Corp has raised approximately $21.7M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Liquidia Corp's estimated valuation?
Provath's modeled valuation for Liquidia Corp is approximately $616.1M (modeled range $43.5M–$2.0B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Liquidia Corp at?
Liquidia Corp's latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Apr 13.
What does Liquidia Corp do and where is it based?
Liquidia Corp operates in the Biotechnology sector, based in Morrisville.
Explore related

See where Liquidia Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Liquidia Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.